Stay updated with breaking news from Nasdaq Cdtx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cantor Fitzgerald restated their overweight rating on shares of Cidara Therapeutics (NASDAQ:CDTX – Free Report) in a report published on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $5.00 price objective on the biotechnology company’s stock. A number of other brokerages have also commented on CDTX. StockNews.com initiated coverage on shares of Cidara Therapeutics […]
HC Wainwright reissued their buy rating on shares of Cidara Therapeutics (NASDAQ:CDTX – Free Report) in a research note released on Tuesday morning, Benzinga reports. HC Wainwright currently has a $6.00 price target on the biotechnology company’s stock. Other analysts also recently issued reports about the company. Cantor Fitzgerald reaffirmed an overweight rating and set […]
Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) was the recipient of a large decline in short interest in the month of July. As of July 15th, there was short interest totalling 1,630,000 shares, a decline of 6.9% from the June 30th total of 1,750,000 shares. Based on an average trading volume of 975,700 shares, […]
Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) was the recipient of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 1,750,000 shares, an increase of 17.4% from the June 15th total of 1,490,000 shares. Based on an average daily trading volume, of 1,070,000 […]
Cidara Therapeutics, Inc. (NASDAQ:CDTX – Get Free Report) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 1,750,000 shares, a growth of 17.4% from the June 15th total of 1,490,000 shares. Based on an average trading volume of 1,070,000 shares, the days-to-cover ratio […]